A Study of Patients Hospitalized With Acute Heart Failure With Reduced Ejection Fraction (HFrEF)
- Conditions
- Heart Failure
- Registration Number
- NCT03515655
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
A study of participants hospitalized with acute heart failure with reduced ejection fraction
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 99209
Inclusion Criteria
- An average left ventricular ejection fraction (LVEF) < 40% over the entire index hospitalization
- Age 18 years or older on the index date
- At least 6 months of activity in the databaseprior to the index date
Exclusion Criteria
- Any code for myocardial infarction (ICD-9 diagnosis code: 410.xx, ICD-10 diagnosis code: I21.xx) or related terms such as "myocardial infarction", "mi", "infarct" or "heart attack" occurring during the index hospitalization
Other protocol defined inclusion/exclusion criteria could apply
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of participants hospitalized with AHF with reduced ejection fraction 6 years Incidence of 30 day mortality 30 days Incidence of 30 day readmission 30 days Incidence of a prolonged length of stay 30 days
- Secondary Outcome Measures
Name Time Method Distribution of socio-demographic characteristics in participants hospitalized for acute HFrEF 6 years Socio-demographic characteristics will be summarized using descriptive statistics
Distribution of clinical characteristics in participants hospitalized for acute HFrEF 6 years Clinical characteristics will be summarized using descriptive statistics
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie acute heart failure with reduced ejection fraction (HFrEF) in NCT03515655?
How does the observational study NCT03515655 compare HFrEF outcomes to standard-of-care treatments?
What biomarkers are associated with patient selection and response prediction in acute HFrEF hospitalizations?
What adverse events are reported in large-scale observational studies of HFrEF like NCT03515655?
How do SGLT2 inhibitors and beta-blockers compare in managing HFrEF as studied in NCT03515655?
Trial Locations
- Locations (1)
Local Institution
🇺🇸Princeton, New Jersey, United States
Local Institution🇺🇸Princeton, New Jersey, United States